In recent years, sodium-glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs) have drawn attention as promising treatments for CKD, with many studies demonstrating their renal and cardiovascular benefits [26, 39–41]. Here, NR3C2 is linked to chronic kidney disease.